Printer Friendly

Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease.

1. Introduction

Systemic sclerosis is an autoimmune systemic disease characterized by diffuse fibrosis and vasculopathy. The diffuse alteration of small blood vessel leads to tissue ischemia and fibroblast stimulation, which result in accumulation of collagen in the skin and internal organs [1]. Patients with SSc can be classified into distinct clinical categories, characterized by different outcomes and life expectancy [2]. According to the extent of skin involvement, patients are classified as limited cutaneous scleroderma (lcSSc) and diffuse cutaneous scleroderma (dcSSc) [3]. In lcSSc, fibrosis is mainly restricted to the hands, arms, and face. Raynaud's phenomenon is generally present for several years before fibrosis appears and pulmonary hypertension represents a frequent clinical complication. In dcSSc, which represents a rapidly progressing disease, a large area of the skin is affected by fibrosis which extends to one or more internal organs. Autoantibodies characteristically targeting nuclear antigens are recognised as one of the hallmarks of SSc and their presence is considered a key feature for the diagnosis. In addition, the presence of different types of antinuclear antibodies (ANAs) appears to be associated with distinct outcomes of the disease including clinical severity [4]. Although the current criteria of the American College of Rheumatology for SSc staging do not include the presence of ANAs [5, 6], their detection might offer an additional tool for the clinical management of the disease, since they might help distinguish patients with an early SSc from those presenting an undifferentiated connective tissue disease (UCTD). According to the more recently proposed criteria [7], UCTD is characterized by a persistent oligosymptomatic condition (at least 3 years) which might evolve into aggressive autoimmune diseases as SSc, systemic lupus erythematosus, primary Sjogren's syndrome, mixed connective tissue disease (MCTD), systemic vasculitis, polydermatomyositis (PM/DM), and rheumatoid arthritis (RA) [8]. The laboratory determination of the autoantibody profile represents a useful tool for both diagnosis and characterization of distinct clinical manifestations of autoimmune diseases; however, their presence or titer tends to persist during the course of the disease, even following therapeutic interventions [4]. Indeed, both in SSC and UCTD the role of autoantibodies in inducing the disease is, as yet, unclear [9]. However, some authors have reported a favorable outcome in SSc patients who lose anti-topo I antibody during the disease course [10], and previous studies have shown a marked reduction of organ inflammation following the suppression of autoantibody production both in human [11] and experimental lupus [12], strongly, though indirectly, suggesting that antibodies reacting with self-components can trigger a chronic, site-specific, inflammation, which, in turn, can be responsible for organ damage. In this view, accumulating evidence has pointed at the pivotal role played by T reg cells in autoimmune diseases, since these cells are key for the regulation, including the initiation as well as the termination, of the adaptive immune response [13]. Previous studies suggested that T reg cells may play a role either in controlling autoantibody production [14] or in limiting autoantibody-induced inflammation through IL-10 production [15, 16] or downregulation of costimulatory molecules on APCs [17]. In order to identify "disease biomarkers" useful for the clinical and therapeutic management of autoimmune disorders, in the present study we assessed an extended panel of nuclear, nucleolar, and cytoplasmic autoantigens, including those associated with SSc (Topoisomerase-I, Cenp-A/B, RNAP III, Th/To, Fibrillarin, PDGFR) as well as dermatomyositis (Mi-2, Jo-1, PL-7, PL-12, EJ, OJ, SRP) or other overlapping syndromes (PM-Scl 75 e PM Scl 100, Ku, Ro-52, NOR 90) [18] facing the determination of the regulatory T cell levels in patients with different clinical forms of SSc and in subjects presenting with a UCTD.

2. Patients and Methods

2.1. Study Design. A cross-sectional study was performed on consecutive patients with diagnosed or suspected SSc incoming the autoimmune outpatients' clinical department (San Gallicano Dermatology Institute) between January 2011 and December 2012. The diagnosis of cSSc was based on the presence of the Raynaud phenomenon associated to abnormal nailfold capillary examination and dermal skin thickness evaluated by clinical palpation of 17 areas of the body [19]. In limited disease (lcSSc) cutaneous involvement was distal to the elbows, knees, and clavicles; in diffuse disease (dcSSc) cutaneous involvement was present also in arms, chest, abdomen, back, or thighs according to the classification criteria established by Carwile LeRoy et al. [3, 20]. Blood samples were collected upon informed consent at the time of the first medical examination and consisted of 3 mL EDTA for flow cytometry analysis and 3 mL for serological assays.

2.2. Patients. The diagnosis of UCTD was based on clinical and serological manifestations suggesting a systemic connective autoimmune disease (arthralgias, Raynaud's disease, ANA reactivity different from antitopoisomerase I and anticentromere, disease duration) [7]. Forty-eight patients were examined in the study: 11 had dcSSc, 14 had lcSSc, and 23 were diagnosed as UCTD. Forty-five of them were women and 3 men. The median age and disease duration from diagnosis to blood sampling as well as a description of the clinical symptoms are summarized in Table 1. All patients were under therapy with 0,5-2 ng of iloprost/kg/min. The control group was composed by 15 healthcare workers, 12F/3 M, median age 53yrs (range 36-64). All subjects were enrolled upon signature of written informed consent.

2.3. Autoantibodies. An immunofluorescence assay (IFA) (Kallestad HEp-2 cell line substrate, Bio-Rad Laboratories, Redmond, WA) was used to detect SSc-associated autoantibodies. An IFA titre greater than 1: 80 dilution was considered positive and the specific fluorescence pattern was recorded. Sera were further analyzed by the Bioplex 2200 ANA screen system (Bio-Rad Laboratories, Hercules, CA), a fully automated system based on multiplexed bead technology, which allows the simultaneous detection of different autoantibodies directed toward a panel of autoantigens including dsDNA, chromatin, centromere-B, Scl-70, RNP (68kDa, RNP-A), SSA (52 and 68kDa), SSB, Sm, Sm/RNP, P ribosomal, and Jo-1. The sera were further tested by two distinct immunoblot assays (Euroline Systemic Sclerosis Nucleoli profile and Euro-line Myositis profile, Euroimmun, Germany, resp.) against purified (Scl-70) or recombinant nuclear (CENP A and CENP B, SSA 52, Ku, Mi-2), nucleolar (Th/To, RNAP III, Fibrillarin, NOR 90, PM-Scl 75, PM-Scl 100), and cytoplasmic antigens (Jo-1, SRP, PL-7, PL-12, EJ, OJ), following the manufacturer's instructions.

2.4. Immunophenotyping. Peripheral blood lymphocyte subsets were examined by flow cytometry. Absolute lymphocyte counts were determined by BD FACSCanto II flow cytometer using BD FACSCanto clinical software v2.4 (BD Biosciences) after incubation of 50 [micro]L of whole blood with 20 uL of a mix of monoclonal antibodies (anti-CD45/CD3/CD4/CD8/CD19/CD16-CD56, BD Multitest 6color TBNK reagent; BD Trucount tubes). T regulatory cells were identified through surface expression of CD4/CD25 antigens and intracellular expression of FoxP3 (Human T reg Flow Kit, Biolegend, San Diego, CA).

2.5. Statistical Analysis. The results (i.e., different responses toward distinct antigens) were compared by contingency tables and [CHI SQUARE] values using the GraphPad Prism5 software (GraphPad Software, Inc., San Diego, CA, USA). The relationship between clinical parameters and serological profiles was assessed by Multiple Correspondence Analysis of data using the SPSS software (SPSS Statistics for Windows, Version 19.0. IBM Corp. Armonk, NY). Resultsoflymphocytesubsets, including T regulatory cells, were compared among the different subject groups by nonparametric test using the GraphPad Prism5 software (GraphPad Software, Inc., San Diego, CA, USA).

3. Results

3.1. Autoantibody Profiles. The frequency of antinuclear antibodies and the distribution of the different fluorescence patterns are shown in Table 2. All patients with lcSSc had antinuclear antibodies as determined by IFA. These were mainly directed against centromeric antigens (78,6%). Patients with dcSSc had antibodies against both nuclear and nucleolar antigens in 54,5% of cases while UCTD patients had speckled antinuclear (65,2%) or antinucleolar (21.7%) responses. The antibody profiles determined by Bioplex and immunoblot are summarized in Table 3. None of the collected sera had antibodies against fibrillarin, OJ, or EJ as well as Th/To antigens. As expected, a highly significant association was found between production of anti-Cenp A/B antibodies and lcSSc as well as between anti Scl-70 and dcSSc. A significantly high frequency of patients with dcSSc had also antibodies against PL-7/12 or sRp antigens (27.3% and 36.4%, resp.). Among UCTD patients two subgroups could be distinguished on the basis of anti-PM-Scl (26.0%) or anti-RNP (30.4%) antibodies. Multiple correspondence analysis (MCA), a descriptive and exploratory technique designed to analyze simple two-way and multiway data, was used to evaluate the possible association among the production of specific antibodies and the clinical outcome. These data, which are shown in Figure 1, further confirmed the recognized association between lcSSc and anti-Cenp A/B as well as between dcSSc and anti-Scl70 antibodies. Interestingly, anti-PM/Scl responses were mainly associated to patients with UCTD.

3.2. Lymphocyte Subsets. The analysis of lymphocyte subsets is described in Table 4. The results showed that patients with SSc, either affected by lcSSc or dcSSc, have higher T cell counts and significantly lower frequencies of T reg cells (also depicted in Figure 2) as compared to UCTD patients or to healthy controls. To further explore the setting of T reg cells during the progression of the disease, the relationship between T reg cell levels and disease duration was examined (Figure 3). The results showed a significant correlation between disease duration and reduced T reg cell percentages (Figure 3(a)), although a strong statistical significancewas foundonly in the group of patients with lcSSc (Figure 3(c)).

4. Discussion and Conclusions

In the present paper,we have assessed an expanded profile of autoantibodies and determined the levels of peripheral T reg cells in patients with SSc, including either limited or diffuse disease, and in patients presenting with clinical signs and symptoms of UCTD, in order to identify disease biomarkers useful for the clinical and therapeutic management. The results indicate that testing an extended antibody profile may provide possible advantages for the clinical classification of patients with SSc and UCTD, while assessing the levels of T reg lymphocytes might help monitoring disease progression. In fact, a multiparametric profiling of antibodies directed towards nuclear, nucleolar, and cytoplasmic antigens, including well-recognized molecules as well as less frequently studied antigens helped at identifying distinctively different clinical outcomes. The use of an extended panel of antigens, mainly related to PM or DM, has been previously proposed in order to identify SSc patients with overlapping syndromes [21]. None of our patients had clinical evidence of an overlapping syndrome (i.e., PM/SSc). However, antiSRP and anti-PL7/12 antibodies proved useful to identify the most severe clinical forms of SSc, which, in turn, presented with the lowest levels of T reg cells. As previously described from different authors, we also found an association between anticentromeric antigens and lcSSc or antitopoisomerase-I and dcSSc [21]. In fact, according to the analysis of results from EULAR study, ACA and antitopoisomerasi are independent predictors of disease presentation/organ involvement [22]. However, in this latter clinical setting, corresponding to the most severe of the autoimmune disorders included in this study, we found also a significatively higher prevalence of antisignal recognition particle (SRP) and/or anti-PL-7/12 antibodies as compared to the lcSSc or the UCTD syndromes. SRP is a ribonuclear protein that regulates protein traslocation across the endoplasmic reticulum membrane during protein synthesis. Anti-SRP antibodies were initially found in patients with PM [20], and they have been subsequently recognized as myositis-specific antibodies [23]. However, the presence of anti-SRP antibodies has been occasionally reported in patients with other immunologic disorders, including SSc, however in the absence of an evident myopathy [24]. Nevertheless, skeletal muscle involvement represents a well-recognized characteristic of SSc [25-28]. Anti-PL7, threonyl-tRNA synthetase, and anti-PL-12, alanyl-tRNA synthetase, antibodies have been previously implicated in the pathogenesis of the antisynthetase syndrome, a disease characterized by varying degrees of interstitial lung disease, myositis, arthropathy, fever, Raynaud's phenomenon, and mechanic's hands [29]. A recent analysis of the clinical profile of patients with connective tissue disease, anti-PL-12 autoantibodies suggest a strong association with idiopathic lung fibrosis rather than myositis or arthritis [30]. In the group of UCTD patients examined in the present study, two main autoantibodies were present: anti-RNP or anti-PM/Scl antibodies. Anti-RNP have been associated with the mixed connective tissue disease (MCTD) while anti-PM-Scl antibodies have been described in SSc patients with milder symptoms, eventually susceptible to evolve to SSc within 5-15 years from the onset of clinical symptoms [31]. However, these patients presented a stable clinical outcome characterized by the presence of typical RP/SSc-like capillaroscopic findings during a period of several years of followup. A clinical and laboratory followup over a more extended period could be necessary to establish or exclude the eventual evolution towards a definite connective disease.

The assessment of T reg lymphocytes may represent an important parameter to measure the immune dysregulation underlying autoimmune disorders. In fact, by either initiating or terminating the adaptive immune response [13], T reg cells may play a central role in the pathogenesis of autoimmunity. It has been shown that an increased expression of genes associated with SSc susceptibility and/or disease manifestations plays a major role also in the regulation of the immune system [32]. Furthermore, an inadequate number of T reg lymphocytes can lead to autoimmunity in humans, as it is clearly shown in patients with immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome, who completely lack T reg cells as results of a mutation in FoxP3 [33]. Indeed, recent studies aimed at assessing the number of T reg cells, pointed at a decrease of T reg frequencies in individuals with immunologic disorders such as rheumatic diseases, including scleroderma [34-36]. However, authors which previously afforded the analysis of T cell reg in SSc patients, underlined an alteration of T cell homeostasis in these patients with an increase of peripheral CD4 T cells and of T reg cells, correlated to disease severity [37, 38] or irrespective of disease phenotype but associated to an impaired regulatory function [39]. In the present study, the results of the analysis of lymphocyte subsets confirmed an increase of CD4 T cells, but in association with a decrease of the frequency of CD4 T reg lymphocytes in SSc patients. In fact, decreased percentages of T reg lymphocytes were found either in the limited or the diffuse disease, although in the dcSSc, which arise as severe clinical condition, their levels do not vary with disease duration, and in the lcSSc, which can be milder at the onset but advance with time, T reg levels decrease according to disease duration, suggesting a relationship between the setting of T reg cells and the progression of the disease. Of note, these results did not depend upon therapeutic intervention since all the patients examined in this study underwent the same therapeutic protocol (iloprost 0,5-2,0 ng/kg/min). This notion also suggests that such therapeutic intervention, though effective at ameliorating some clinical signs and symptoms, exerts a limited impact on regulatory immune circuitries, which appears to play a key pathogenic role and to be chronically and progressively altered in autoimmune disorders. This further emphasizes the need of novel therapeutic strategies capable of targeting regulatory cells/signals involved in the generation and termination of the adaptive immune response. In fact, although numerous studies have focused on the pathogenic mechanism of immune activation and tissue fibrosis in SSc [40] and potential therapeutic targets have been identified [41], efficacious treatment strategy for this disease has not been established yet.

Taken together, our data indicate the following: (i) dcSSc, which corresponds to a severe autoimmune disorder and is associated to the presence of several class of autoantibodies, presents with very low levels of T regs, which do not appear to depend upon disease duration; (ii) lcSSc, which is characterized by high titers of anti-centromere antibodies from the earlierclinicalstagesand generallystartswithmildsymptoms which progress during time, presents levels of T reg which are progressively lower in association with disease duration; (iii) UCTD, which is characterized by an undifferentiated onset, which could remain clinically undetermined for an indefinite time or may even show a clinical remission [8], presents with a reduced spectrum and low levels of autoantibodies and shows levels of T reg which are comparable to healthy controls. These observations support the notion that T reg lymphocytes may play a central role in the pathogenesis of SSc and that the determination of the levels of peripheral T reg cells may represent a useful tool in the diagnosis, prognosis, and monitoring of patients presenting with clinical signs and symptoms of autoimmune inflammatory diseases and might prove a key disease biomarker for the clinical and therapeutic management of major autoimmune disorders.

http://dx.doi.org/10.1155/2013/390563

References

[1] A. Gabrielli, E. V. Avvedimento, and T. Krieg, "Mechanisms of disease: scleroderma," The New England Journal of Medicine, vol. 360, no. 19, pp. 1989-2003, 2009.

[2] E. Hachulla and D. Launay, "Diagnosis and classification of systemic sclerosis," Clinical Reviews in Allergy and Immunology, vol. 40, no. 2, pp. 78-83, 2011.

[3] E. Carwile LeRoy, C. Black, R. Fleischmajer et al., "Scleroderma (systemic sclerosis): classification, subsets and pathogenesis," Journal of Rheumatology, vol. 15, no. 2, pp. 202-205, 1988.

[4] Y. Hamaguchi, "Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis," Journal of Dermatology, vol. 37, no. 1, pp. 42-53, 2010.

[5] Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, "Preliminary criteria for the classification of systemic sclerosis (scleroderma)," Arthritis & Rheumatism, vol. 23, no. 5, pp. 581-590, 1980.

[6] O. Nadashkevich, P. Davis, and M. J. Fritzler, "A proposal of criteria for the classification of systemic sclerosis," Medical Science Monitor, vol. 10, no. 11, pp. CR615-CR621, 2004.

[7] M. Mosca, C. Tani, R. Talarico, and S. Bombardieri, "Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases," Autoimmunity Reviews, vol. 10, no. 5, pp. 256-258, 2011.

[8] M. Mosca, C. Tani, and S. Bombardieri, "Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology," Best Practice and Research, vol. 21, no. 6, pp. 1011-1023, 2007

[9] A. Gabrielli, S. Svegliati, G. Moroncini, and E. V Avvedimento, "Pathogenic autoantibodies in systemic sclerosis," Current Opinion in Immunology, vol. 19, no. 6, pp. 640-645, 2007

[10] M. Kuwana, J. Kaburaki, T Mimori, Y. Kawakami, and T. Tojo, "Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis 2000," Arthritis & Rheumatism, vol. 43, no. 5, pp. 1074-1084, 2000.

[11] T. Y. T. Lu, K. P. Ng, G. Cambridge et al., "A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients," Arthritis Care and Research, vol. 61, no. 4, pp. 482-487, 2009.

[12] K. Neubert, S. Meister, K. Moser et al., "The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis," Nature Medicine, vol. 14, no. 7, pp. 748-755, 2008.

[13] S. Sakaguchi, M. Miyara, C. M. Costantino, and D. A. Hafler, "FOXP3 + regulatory T cells in the human immune system," Nature Reviews Immunology, vol. 10, no. 7, pp. 490-500, 2010.

[14] K. Fujio, T. Okamura, S. Sumitomo, and K. Yamamoto, "Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity," Annals of the Rheumatic Diseases, vol. 72, pp. ii85-ii89, 2013.

[15] S. Huber, N. Gagliani, E. Esplugues et al., "Th17 cells express IL10 receptor and are controlled by Foxp3 and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner," Immunity, vol. 34, no. 4, pp. 554-565, 2011.

[16] A. Chaudhry, D. Rudra, P. Treuting et al., "CD4+ regulatory T cells control TH17 responses in a stat3-dependent manner," Science, vol. 326, no. 5955, pp. 986-991, 2009.

[17] L. Cederbom, H. Hall, and F. Ivars, "CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells," European Journal of Immunology, vol. 30, pp. 1538-1543, 2000.

[18] S. Mehra, J. Walker, K. Patterson, and M. J. Fritzler, "Autoantibodies in systemic sclerosis," Autoimmunity Reviews, vol. 12, pp. 340-354, 2013.

[19] D. E. Furst, P. J. Clements, V. D. Steen et al., "The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis," Journal of Rheumatology, vol. 25, no. 1, pp. 84-88, 1998.

[20] E. C. LeRoy and T. A. Medsger Jr., "Criteria for the classification of early systemic sclerosis," Journal of Rheumatology, vol. 28, no. 7, pp. 1573-1576, 2001.

[21] A. Balbir-Gurman and Y. Braun-Moscovici, "Scleroderma overlap syndrome," Israel Medical Association Journal, vol. 13, no. 1, pp. 14-20, 2011.

[22] U. A. Walker, A. Tyndall, L. Czirjak et al., "Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database," Annals of the Rheumatic Diseases, vol. 66, pp. 754-763, 2007.

[23] I. N. Targoff, A. E. Johnson, and F. W. Miller, "Antibodyto signal recognition particle in polymyositis," Arthritis & Rheumatism, vol. 33, no. 9, pp. 1361-1370, 1990.

[24] A. H. Kao, D. Lacomis, M. Lucas, N. Fertig, and C. V Oddis, "Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy," Arthritis & Rheumatism, vol. 50, no. 1, pp. 209-215, 2004.

[25] M. C. Tamby, Y. Chanseaud, L. Guillevin, and L. Mouthon, "New insights into the pathogenesis of systemic sclerosis," Autoimmunity Reviews, vol. 2, no. 3, pp. 152-157, 2003.

[26] Y. Mimura, H. Ihn, M. Jinnin, Y. Asano, K. Yamane, and K. Tamaki, "Clinical and laboratory features of scleroderma patients developing skeletal myopathy," Clinical Rheumatology, vol. 24, no. 2, pp. 99-102, 2005.

[27] B. Ranque, F. J. Authier, V. Le-Guern et al., "A descriptive and prognostic study of systemic sclerosis-associated myopathies," Annals of the Rheumatic Diseases, vol. 68, no. 9, pp. 1474-1477, 2009.

[28] S. Partovi, A. C. Schulte, M. Aschwanden et al., "Impaired skeletal muscle microcirculation in systemic sclerosis," Arthritis Research & Therapy, vol. 14, no. 5, article R209, 2012.

[29] E. Katzap, M. L. Barilla-Labarca, and G. Marder, "Anti-synthetase syndrome," Current Rheumatology Reports, vol. 13, no. 3, pp. 175-181, 2011.

[30] M. Kalluri, S. A. Sahn, C. V Oddis et al., "Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature," Chest, vol. 135, no. 6, pp. 1550-1556, 2009.

[31] R. W. Koschik, N. Fertig, M. R. Lucas, R. T. Domsic, and T. A. Medsger Jr., "Anti-PM-Scl antibody in patients with systemic sclerosis," Clinical and Experimental Rheumatology, vol. 30, no. 2, supplement 71, pp. s12-s16, 2012.

[32] J. L. Sargent and M. L. Whitfield, "Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling," Expert Review of Clinical Immunology, vol. 7, no. 4, pp. 463-473, 2011.

[33] R. S. Wildin, S. Smyk-Pearson, and A. H. Filipovich, "Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome," Journal of Medical Genetics, vol. 39, no. 8, pp. 537-545, 2002.

[34] E. Antiga, P. Quaglino, S. Bellandi et al., "Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea," British Journal of Dermatology, vol. 162, no. 5, pp. 1056-1063, 2010.

[35] M. R. Jocea, M. van Amelsfort, G. J. Walter, and L. S. Taams, "CD4+CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases," Expert Review of Clinical Immunology, vol. 7, no. 4, pp. 499-514, 2011.

[36] D. Fenoglio, F. Battaglia, A. Parodi et al., "Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis," Clinical Immunology, vol. 139, no. 3, pp. 249-257, 2011.

[37] A. Giovannetti, E. Rosato, C. Renzi et al., "Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes," Clinical Immunology, vol. 137, no. 1, pp. 122-133, 2010.

[38] G. Slobodin, M. S. Ahmad, I. Rosner et al., "Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity," Cellular Immunology, vol. 261, no. 2, pp. 77-80, 2010.

[39] T. R. D. J. Radstake, L. van Bon, J. Broen et al., "Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGF[beta] expression," PLoS ONE, vol. 4, no. 6, Article ID e5981, 2009.

[40] T. R. Katsumoto, M. L. Whitfield, and M. K. Connolly, "The pathogenesis of systemic sclerosis," Annual Review of Pathology, vol. 6, pp. 509-537, 2011.

[41] M. Hasegawa and K. Takehara, "Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines," Seminars in Arthritis and Rheumatism, vol. 42, pp. 281-296, 2012.

Paola Cordiali-Fei, (1) Anna Mussi, (2) Giovanna D'Agosto, (1) Elisabetta Trento, (1) Valentina Bordignon, (1) Silvana Trincone, (2) Antonella Vento, (1) Isabella Sperduti, (3) Antonio Cristaudo, (2) and Fabrizio Ensoli (1)

(1) Clinical Pathology and Microbiology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy

(2) Clinical Dermatology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy

(3) Biostatistic Unit, Regina Elena CancerInstitute, Via Elio Chianesi 53, 00144 Rome, Italy

Correspondence should be addressed to Paola Cordiali-Fei; cordiali-fei@ifo.it

Received 28 January 2013; Revised 21 March 2013; Accepted 11 April 2013

Academic Editor: Nicolaus Kroger

TABLE 1: Clinical and demographic characteristics of patients.

                              lcSSc        dcSSc         UCTD
Sex                            (14)         (11)         (23)

                               14/0         8/3          23/0

Age range                   41-66 (56)   35-80 (68)   18-73 (51)
  (median yrs)
Disease duration range      7-20 (12)    6-30 (24)     3-20 (8)
  (median yrs)
Raynaud's phenomenon P/N       14/0         11/0         23/0
Fingertip ulcers P/N           14/0         11/0         14/9
Pulmonary arterial             0/14         7/4          2/21
  hypertension P/N
Pulmunary fibrosis P/N         0/14         7/4          0/23
Therapy (iloprost)             Yes          Yes          Yes

TABLE 2: Frequency of anti-nuclear
antibodies and fluoroscopic patterns.

Anti-nuclear          lcSSc (14)        Diagnosis
antibodies (ANA)                       dcSSc (11)

P/N                   14 (100%)          8 (73%)
Titer                   1:5120           1: 5120
(range)            (1: 640-1: 5120)   (1:80-1:5120)
Centromere           11 (78.6%) #       1 (12.5%)
Nucleolar             3 (21.4%)             0
Homogeneous and           0            6 (75.0%) #
  nucleolar
Speckled                  0                 0
Mitotic Spindle           0             1 (12.5%)

Anti-nuclear          UCTD (23)         P
antibodies (ANA)

P/N                   20 (87%)
Titer                   1:320
(range)            (1: 80-1: 1280)
Centromere                0          <0.0001
Nucleolar             5 (25.0%)       n.s.
Homogeneous and           0          <0.0001
  nucleolar
Speckled            15 (75.0%) #     <0.0001
Mitotic Spindle           0           n.s.

# = bold

TABLE 3: Frequency of reactivity to nuclear,
nucleolar, or cytoplasmic antigens.

                                Diagnosis

Antibody           lcSSc (14)    dcSSc (11)   UCTD (23)      P
reactivity
                      P/N           P/N          P/N

ANA (I.F.A.)          14/0         11/0         18/5       0.02
Cenp-A/B              11/3          3/8         0/23      <0.0001
Scl-70                0/14          6/5         0/23      <0.0001
Ro-52                 2/12          3/8         1/22
RNP                   0/14         0/11         7/16       0.011
Mi-2                  1/13         1/10         0/23
PM/Scl                1/13         1/10         5/18
NOR                   2/12         1/10         2/21
Ku                    1/13          2/9         3/20
RP                    1/13         0/11         1/22
PL-7-12               0/14          3/8         0/23       0.005
SRP                   0/14          4/7         1/22       0.005
Jo-1                  0/14         0/11         0/23
[greater than or      4/7           8/6         3/20       0.017
  equal to]2
  antigens

TABLE 4: Peripheral lymphocyte subsets
including T reg cells in patients and controls.

                                Lymphocyte subsets

                CD3+         CD3+CD4+       CD3+CD8+        CD19+
Diagnosis      n/mmc          n/mmc          n/mmc          n/mmc
            median value   median value   median value     median
               range          range          range       value range

lcSSc          1538 *         1196 *          351            250
             1004-2666       683-1939       221-727        99-763
dcSSc          1704 *         1317 *          506            159
              952-3426       592-2637       170-938        45-1031
UCTD            1308           967            437            181
              490-2506       282-1830       143-694        36-866
CTRLS           1160           840            504            231
             1300-1680       738-1040       272-760        100-310
P             <0.0001         0.0003         0.0800        0.0440

                         Lymphocyte subsets

             CD16+CD56+      CD4/CD8      CD4/CD25/FoxP3
Diagnosis      n/mmc          ratio       % of CD4+ cells
            median value   median value    median value
               range          range            range

lcSSc           162           3.05 *          1.67 *
               54-475       1.88-4.53        1.21-3.27
dcSSc           158            2.99           1.85 *
               90-752        1.11-7.1        1.22-3.21
UCTD            186            2.30            2.90
               25-397       0.56-5.11        0.4-4.90
CTRLS           294            2.10            2.10
              100-810        1.2-2.9          1.1-3.2
P              0.0860         0.0007          0.0030
COPYRIGHT 2013 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Clinical Study
Author:Cordiali-Fei, Paola; Mussi, Anna; D'Agosto, Giovanna; Trento, Elisabetta; Bordignon, Valentina; Trin
Publication:Journal of Immunology Research
Date:Jan 1, 2013
Words:4671
Previous Article:Interferon-[gamma] triggers hepatic stellate cell-mediated immune regulation through MEK/ERK signaling pathway.
Next Article:Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |